BTK and B-cell chronic lymphocytic leukemia: Most treatment naïve CLL patients will receive either a Bruton tyrosine kinase (BTK) inhibitor or a B‐cell lymphoma 2 (BCL 2) inhibitor at some point in their treatment cycle.